These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16503747)

  • 1. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    Murray TJ
    Expert Opin Drug Saf; 2006 Mar; 5(2):265-74. PubMed ID: 16503747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
    Zingler VC; Nabauer M; Jahn K; Gross A; Hohlfeld R; Brandt T; Strupp M
    Eur Neurol; 2005; 54(1):28-33. PubMed ID: 16088176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone for multiple sclerosis in clinical practice.
    Rizvi SA; Zwibel H; Fox EJ
    Neurology; 2004 Dec; 63(12 Suppl 6):S25-7. PubMed ID: 15623666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR; Herndon R
    Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
    Gonsette RE
    Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    Ramtahal J; Jacob A; Das K; Boggild M
    J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukaemia induced by mitoxantrone: case report.
    Arruda WO; Montú MB; de Oliveira Mde S; Ramina R
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):327-9. PubMed ID: 16100984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
    BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.